These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 20929323)

  • 1. Immunohistochemical expression profile and prognosis in patients with diffuse large B-cell lymphoma with or without human immunodeficiency virus infection.
    Xicoy B; Ribera JM; Mate JL; Tapia G; Morgades M; Navarro JT; Sanz C; Ariza A; Feliu E
    Leuk Lymphoma; 2010 Nov; 51(11):2063-9. PubMed ID: 20929323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characteristics of diffuse large B-cell lymphoma in human immunodeficiency virus-infected and -uninfected patients in the pre-highly active antiretroviral therapy and pre-rituximab era.
    Morton LM; Kim CJ; Weiss LM; Bhatia K; Cockburn M; Hawes D; Wang SS; Chang C; Altekruse SF; Engels EA; Cozen W
    Leuk Lymphoma; 2014 Mar; 55(3):551-7. PubMed ID: 23772639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
    Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS
    Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome.
    Kojima Y; Tsurumi H; Goto N; Shimizu M; Kasahara S; Yamada T; Kanemura N; Hara T; Sawada M; Saio M; Yamada T; Takahashi T; Tomita E; Takami T; Moriwaki H
    Eur J Haematol; 2006 Jun; 76(6):465-72. PubMed ID: 16494623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of the Bcl-2 negative germinal centre in patients with diffuse large B cell lymphoma treated with R-CHOP.
    Song MK; Chung JS; Shin DH; Seol YM; Shin HJ; Choi YJ; Cho GJ
    Leuk Lymphoma; 2009 Jan; 50(1):54-61. PubMed ID: 19152170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
    Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL
    Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue microarrays in diffuse large B-cell lymphomas: are they really able to identify distinct prognostic groups in lymphomas of both nodal and extranodal origin?
    Laszlo D; Pruneri G; Andreola G; Radice D; Calabrese L; Rafaniello PR; Nassi L; Sammassimo S; Alietti A; Agazzi A; Vanazzi A; Martinelli G
    Int J Surg Pathol; 2011 Aug; 19(4):417-24. PubMed ID: 19793830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy.
    Navarro JT; Lloveras N; Ribera JM; Oriol A; Mate JL; Feliu E
    Haematologica; 2005 May; 90(5):704-6. PubMed ID: 15921395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD20-negative de novo diffuse large B-cell lymphoma in HIV-negative patients: a matched case-control analysis in a single institution.
    Li YJ; Li ZM; Rao HL; Xia Y; Huang HQ; Xia ZJ; Li S; Li WY; Jiang WQ
    J Transl Med; 2012 May; 10():84. PubMed ID: 22554077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
    J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical expression of mTOR in germinal center and nongerminal center group of diffuse large B-cell lymphoma: a clinicopathological study.
    Vajpayee N; Burack R; Wang D; Hutchison RE; Gajra A
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):159-63. PubMed ID: 25458080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
    Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
    Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN.
    Fridberg M; Servin A; Anagnostaki L; Linderoth J; Berglund M; Söderberg O; Enblad G; Rosén A; Mustelin T; Jerkeman M; Persson JL; Wingren AG
    Leuk Lymphoma; 2007 Nov; 48(11):2221-32. PubMed ID: 17926183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP.
    Wong KK; Ch'ng ES; Loo SK; Husin A; Muruzabal MA; Møller MB; Pedersen LM; Pomposo MP; Gaafar A; Banham AH; Green TM; Lawrie CH
    Exp Mol Pathol; 2015 Dec; 99(3):537-45. PubMed ID: 26341140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum metabolomic profiling based on GC/MS helped to discriminate Diffuse Large B-cell Lymphoma patients with different prognosis.
    Mi M; Liu Z; Zheng X; Wen Q; Zhu F; Li J; Mungur ID; Zhang L
    Leuk Res; 2021 Dec; 111():106693. PubMed ID: 34455197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma.
    Visco C; Canal F; Parolini C; Andreoli A; Ambrosetti A; Krampera M; Lestani M; Pizzolo G; Chilosi M
    Haematologica; 2006 May; 91(5):687-90. PubMed ID: 16670073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy.
    Hong J; Park S; Park J; Jang SJ; Ahn HK; Sym SJ; Cho EK; Shin DB; Lee JH
    Ann Hematol; 2012 Dec; 91(12):1897-906. PubMed ID: 22864685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determining protein biomarkers for DLBCL using FFPE tissues from HIV negative and HIV positive patients.
    Magangane P; Sookhayi R; Govender D; Naidoo R
    J Mol Histol; 2016 Dec; 47(6):565-577. PubMed ID: 27696080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunophenotypes and prognosis of diffuse large B-cell lymphoma: a study of 500 cases].
    Luo DL; Liu YH; Zhuang HG; Li L; Xu FP; Zhang F; Luo XL; Xu J
    Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):235-9. PubMed ID: 21615996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).
    Carreras J; Kikuti YY; Beà S; Miyaoka M; Hiraiwa S; Ikoma H; Nagao R; Tomita S; Martin-Garcia D; Salaverria I; Sato A; Ichiki A; Roncador G; Garcia JF; Ando K; Campo E; Nakamura N
    Histopathology; 2017 Mar; 70(4):595-621. PubMed ID: 27775850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.